Search Results Heading

MBRLSearchResults

mbrl.module.common.modules.added.book.to.shelf
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
    Done
    Filters
    Reset
  • Discipline
      Discipline
      Clear All
      Discipline
  • Is Peer Reviewed
      Is Peer Reviewed
      Clear All
      Is Peer Reviewed
  • Item Type
      Item Type
      Clear All
      Item Type
  • Subject
      Subject
      Clear All
      Subject
  • Year
      Year
      Clear All
      From:
      -
      To:
  • More Filters
34 result(s) for "Barba, Ignasi"
Sort by:
Lactic Acid in Tumour Biology
Lactic acid accumulates in the tumour microenvironment (TME) at concentrations reaching up to 40 mM. Initially, lactic acid was considered merely a metabolic by-product of aerobic glycolysis, a phenomenon commonly referred to as the Warburg effect and observed in the majority of tumours. Recent evidence, however, has demonstrated that lactic acid is not merely a waste product; rather, it plays a pivotal role in tumour biology. High plasma lactic acid levels correlate with increased metastatic potential and lower survival rates. Elevated lactic acid levels in the TME have been shown to suppress antitumour immune responses, facilitate both metastasis and cellular senescence, and might modulate gene expression through novel epigenetic mechanisms such as histone lactylation. This review aims to summarize current knowledge on the multifaceted impact of elevated lactic acid in the TME on tumour progression and biology.
Targeting the Warburg Effect in Cancer: Where Do We Stand?
The Warburg effect, characterized by the preferential conversion of glucose to lactate even in the presence of oxygen and functional mitochondria, is a prominent metabolic hallmark of cancer cells and has emerged as a promising therapeutic target for cancer therapy. Elevated lactate levels and acidic pH within the tumor microenvironment (TME) resulting from glycolytic profoundly impact various cellular populations, including macrophage reprogramming and impairment of T-cell functionality. Altogether, the Warburg effect has been shown to promote tumor progression and immunosuppression through multiple mechanisms. This review provides an overview of the current understanding of the Warburg effect in cancer and its implications. We summarize recent pharmacological strategies aimed at targeting glycolytic enzymes, highlighting the challenges encountered in achieving therapeutic efficacy. Additionally, we examine the utility of the Warburg effect as an early diagnostic tool. Finally, we discuss the multifaceted roles of lactate within the TME, emphasizing its potential as a therapeutic target to disrupt metabolic interactions between tumor and immune cells, thereby enhancing anti-tumor immunity.
Sex differences in the 1H NMR metabolic profile of serum in cardiovascular risk patients
Personalized diagnosis and risk stratification of cardiovascular diseases would allow optimizing therapeutic strategies and lifestyle changes. Metabolomics is a promising technique for personalized diagnosis and prognosis; however, various physiological parameters, including sex, influence the metabolic profile thus hampering its translation to the clinic. Knowledge of the variation in the metabolic profile associated with sex would facilitate metabolomic translation to the clinic. The objective of the present work was to investigate the possible differences in the metabolic 1 H NMR profile associated to sex beyond lipoproteins. 1 H NMR spectra from whole serum and methanol deproteinized samples from 39 patients (22 males, 17 females) between 55–70 years old with suspected coronary artery disease that underwent a stress test that was considered negative where included. Deproteinized serum could be used to differentiate sex based on higher levels of lactate and glucose in women. Lipoprotein region was the most variable area of the spectra between individuals, but spectra of whole serum were able to differentiate sex based on lipoproteins. There are sex-related differences in the 1 H NMR metabolic profile of individuals with suspected cardiovascular disease beyond lipoproteins. These findings may help the translation of metabolomics to the clinic.
1H NMR serum metabolomic profiling of patients at risk of cardiovascular diseases performing stress test
Cardiovascular diseases are the leading cause of death worldwide. Changes in lifestyle and/or pharmacological treatment are able to reduce the burden of coronary artery diseases (CAD) and early diagnosis is crucial for the timely and optimal management of the disease. Stress testing is a good method to measure the burden of CAD but it is time consuming and pharmacological testing may not fully mimic exercise test. The objectives of the present project were to characterize the metabolic profile of the population undergoing pharmacological and exercise stress testing to evaluate possible differences between them, and to assess the capacity of 1 H NMR spectroscopy to predict positive stress testing. Pattern recognition was applied to 1 H NMR spectra from serum of patients undergoing stress test and metabolites were quantified. The effects of the stress test, confounding variables and the ability to predict ischemia were evaluated using OPLS-DA. There was an increase in lactate and alanine concentrations in post-test samples in patients undergoing exercise test, but not in those submitted to pharmacological testing. However, when considering only pharmacological patients, those with a positive test result, showed increased serum lactate, that was masked by the much larger amount of lactate associated to exercise testing. In conclusion, we have established that pharmacological stress test does not reproduce the dynamic changes observed in exercise stress. Although there is promising evidence suggesting that 1 H NMR based metabolomics could predict stress test results, further studies with much larger populations will be required in order to obtain a definitive answer.
Enhancing Glycolysis Protects against Ischemia-Reperfusion Injury by Reducing ROS Production
After myocardial ischemia-reperfusion, fatty acid oxidation shows fast recovery while glucose oxidation rates remain depressed. A metabolic shift aimed at increasing glucose oxidation has shown to be beneficial in models of myocardial ischemia-reperfusion. However, strategies aimed at increasing glucose consumption in the clinic have provided mixed results and have not yet reached routine clinical practice. A better understanding of the mechanisms underlying the protection afforded by increased glucose oxidation may facilitate the transfer to the clinic. The purpose of this study was to evaluate if the modulation of reactive oxygen species (ROS) was involved in the protection afforded by increased glucose oxidation. Firstly, we characterized an H9C2 cellular model in which the use of glucose or galactose as substrates can modulate glycolysis and oxidative phosphorylation pathways. In this model, there were no differences in morphology, cell number, or ATP and PCr levels. However, galactose-grown cells consumed more oxygen and had an increased Krebs cycle turnover, while cells grown in glucose had increased aerobic glycolysis rate as demonstrated by higher lactate and alanine production. Increased aerobic glycolysis was associated with reduced ROS levels and protected the cells against simulated ischemia-reperfusion injury. Furthermore, ROS scavenger N-acetyl cysteine (NAC) was able to reduce the amount of ROS and to prevent cell death. Lastly, cells grown in galactose showed higher activation of mTOR/Akt signaling pathways. In conclusion, our results provide evidence indicating that metabolic shift towards increased glycolysis reduces mitochondrial ROS production and prevents cell death during ischemia-reperfusion injury.
Author Correction: Selective Inhibition of Succinate Dehydrogenase in Reperfused Myocardium with Intracoronary Malonate Reduces Infarct Size
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk
Succinate is enhanced during initial reperfusion in blood from the coronary sinus in ST-segment elevation myocardial infarction (STEMI) patients and in pigs submitted to transient coronary occlusion. Succinate levels might have a prognostic value, as they may correlate with edema volume or myocardial infarct size. However, blood from the coronary sinus is not routinely obtained in the CathLab. As succinate might be also increased in peripheral blood, we aimed to investigate whether peripheral plasma concentrations of succinate and other metabolites obtained during coronary revascularization correlate with edema volume or infarct size in STEMI patients. Plasma samples were obtained from peripheral blood within the first 10 min of revascularization in 102 STEMI patients included in the COMBAT-MI trial (initial TIMI 1) and from 9 additional patients with restituted coronary blood flow (TIMI 2). Metabolite concentrations were analyzed by 1 H-NMR. Succinate concentration averaged 0.069 ± 0.0073 mmol/L in patients with TIMI flow ≤ 1 and was significantly increased in those with TIMI 2 at admission (0.141 ± 0.058 mmol/L, p  < 0.05). However, regression analysis did not detect any significant correlation between most metabolite concentrations and infarct size, extent of edema or other cardiac magnetic resonance (CMR) variables. In conclusion, spontaneous reperfusion in TIMI 2 patients associates with enhanced succinate levels in peripheral blood, suggesting that succinate release increases overtime following reperfusion. However, early plasma levels of succinate and other metabolites obtained from peripheral blood does not correlate with the degree of irreversible injury or area at risk in STEMI patients, and cannot be considered as predictors of CMR variables. Trial registration: Registered at www.clinicaltrials.gov (NCT02404376) on 31/03/2015. EudraCT number: 2015-001000-58.
Histology-informed microstructural diffusion simulations for MRI cancer characterisation—the Histo-μSim framework
Diffusion Magnetic Resonance Imaging (dMRI) simulations in geometries mimicking the microscopic complexity of human tissues enable the development of innovative biomarkers with unprecedented fidelity to histology. Simulation-informed dMRI has traditionally focussed on brain imaging, and it has neglected other applications, as for example body cancer imaging, where new non-invasive biomarkers are still sought. This article fills this gap by introducing a Monte Carlo diffusion simulation framework informed by histology, for enhanced body dMR microstructural imaging: the Histo- μ Sim approach. We generate dictionaries of synthetic dMRI signals with coupled tissue properties from virtual cancer environments, reconstructed from hematoxylin-eosin stains of human liver biopsies. These enable the data-driven estimation of properties such as the intrinsic extra-cellular diffusivity, cell size or cell membrane permeability. We compare Histo- μ Sim to metrics from well-established analytical multi-compartment models in silico, on fixed mouse tissues scanned ex vivo (kidneys, spleens, and breast tumours) and in cancer patients in vivo. Results suggest that Histo- μ Sim is feasible in clinical settings, and that it delivers metrics that more accurately reflect histology as compared to analytical models. In conclusion, Histo- μ Sim offers histologically-meaningful tissue descriptors that may increase the specificity of dMRI towards cancer, and thus play a crucial role in precision oncology. A histology-informed, diffusion Magnetic Resonance Imaging simulation framework improves the non-invasive assessment of cancer biology in solid tumours in vivo
Connexin 43 Deficiency Is Associated with Reduced Myocardial Scar Size and Attenuated TGFβ1 Signaling after Transient Coronary Occlusion in Conditional Knock-Out Mice
Previous studies demonstrated a reduction in myocardial scar size in heterozygous Cx43+/- mice subjected to permanent coronary occlusion. However, patients presenting with ST segment elevation myocardial infarction often undergo rapid coronary revascularization leading to prompt restoration of coronary flow. Therefore, we aimed to assess changes in scar size and left ventricular remodeling following transient myocardial ischemia (45 min) followed by 14 days of reperfusion using Cx43fl/fl (controls) and Cx43Cre-ER(T)/fl inducible knock-out (Cx43 content: 50%) mice treated with vehicle or 4-hydroxytamoxifen (4-OHT) to induce a Cre-ER(T)-mediated global deletion of the Cx43 floxed allele. The scar area (picrosirius red), measured 14 days after transient coronary occlusion, was similarly reduced in both vehicle and 4-OHT-treated Cx43Cre-ER(T)/fl mice, compared to Cx43fl/fl animals, having normal Cx43 levels (15.78% ± 3.42% and 16.54% ± 2.31% vs. 25.40% ± 3.14% and 22.43% ± 3.88% in vehicle and 4-OHT-treated mice, respectively, p = 0.027). Left ventricular dilatation was significantly attenuated in both Cx43-deficient groups (p = 0.037 for left ventricular end-diastolic diameter). These protective effects were correlated with an attenuated enhancement in pro-transforming growth factor beta 1 (TGFβ1) expression after reperfusion. In conclusion, our data demonstrate that Cx43 deficiency induces a protective effect on scar formation after transient coronary occlusion in mice, an effect associated with reduced left ventricular remodeling and attenuated enhancement in pro-TGFβ1 expression.
Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI
Background Innovative diffusion Magnetic Resonance Imaging (MRI) models enable the non-invasive measurement of cancer biological properties in vivo. However, while cancers frequently spread to the liver, models tailored for liver application and easy to deploy in the clinic are still sought. We fill this gap by delivering a practical, clinically-viable framework for liver tumour diffusion imaging, informing its design through histology. Methods: We compare MRI and histological data from mice and cancer patients, namely: MRI and hemaotxylin-eosin (HE) stains from N = 7 fixed mouse livers; MRI of N = 38 patients suffering from liver solid tumours, N = 18 of whom with HE biopsies. We study five diffusion models, ranking them according to a total MRI-histology correlation score. Afterwards, we test metrics from the top-ranking model on our cohort, assessing their sensitivity to cell proliferation (Ki-67 staining, N = 10), evaluating their association with tumour volume (N = 140 tumours), and comparing them across primary cancer types. Results: We select a dMRI signal model of restricted intra-cellular diffusion with negligible extra-cellular contributions, which maximises radiological-histological correlations (total score: 0.625). The model provides cell size and density estimates that i) correlate with histology (e.g., for cell size: r = 0.44, p = 0.029), ii) are associated to Ki-67 cell proliferation (for MRI cell density: r = 0.80, p = 0.006) and tumour volume (r = 0.40, p < 10 –5 for tumour volume regression), and iii) that distinguish melanoma (N = 8) from colorectal cancer (N = 13) (p = 0.011 for intra-cellular fraction). Conclusions: Our biologically meaningful approach may complement standard-of-care radiology, and become a new tool for enhanced cancer characterisation in precision oncology. Plain language summary Magnetic Resonance Imaging (MRI) is an imaging tool used frequently to detect and monitor malignant tumours. Notably, the latest MRI technology enables physicians to measure not only the size of a tumour, but even properties related to the cells it contains. This information, like number or size of cells can help oncologists to choose the best treatment. Obtaining this information using this imaging tool in tumors that have spread to the liver, remained challenging. Here we present an MRI method developed specifically to capture the biology of liver tumour cells. We base it on mathematical models that use information gathered from microscopy images – known as histology, where individual cells are visible – to guide the analysis of the scan. We show that the method quantifies tumour cell size and density from a simple, clinically feasible MRI scan and propose this technique for oncological applications. Grussu et al. use co-localised MRI and histology data to design a practical MRI technique for cell size and density measurement in liver tumours in vivo. The method provides non-invasive proxies of histological properties that are associated to cell proliferation, that explain tumour volume and that distinguish liver tumour types.